Natural antioxidant biomolecules promises future nanomedicine based therapy for cataract

Colloids and Surfaces B: Biointerfaces

Volumn 112, Issue , 2013, Pages 554-562

  Sunkireddy, Pavan ^a   Jha, Shashi Nath ^b   Kanwar, Jagat R ^c   Yadav, Subhash C ^a  

^a THE ENERGY AND RESOURCES INSTITUTE   (India)

^b SIR GANGA RAM HOSPITAL   (India)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Ayurvedic treatment; Carotenoids; Flavonoids; Nanoencapsulation; Oxidative modification; Phase separation

Indexed keywords

AYURVEDIC TREATMENT; CAROTENOIDS; CATARACT FORMATION; NANO-ENCAPSULATION; NATURAL ANTIOXIDANTS; OXIDATIVE MODIFICATION; THERAPEUTIC POTENTIALS; TOPICAL APPLICATION;

BIOCHEMISTRY; BIOMOLECULES; FLAVONOIDS; MEDICAL NANOTECHNOLOGY; PHASE SEPARATION;

ANTIOXIDANTS;

ACETYLSALICYLIC ACID; ANGELICIN; ANTIOXIDANT; ASCORBIC ACID; AYURVEDIC DRUG; CARNOSINE; CAROTENOID; CHLOROGENIC ACID; CIPROFLOXACIN; FLAVONOID; FLURBIPROFEN; GALLIC ACID; GINKGO BILOBA EXTRACT; GONADORELIN AGONIST; IBUPROFEN; LACTOFERRIN; LYCOPENE; MOMORDICA CHARANTIA EXTRACT; MORINGA OLEIFERA EXTRACT; NANOCARRIER; NUTRACEUTICAL; OCIMUM SANCTUM EXTRACT; PARACETAMOL; PHENOL DERIVATIVE; SILIBININ; SOUR ORANGE EXTRACT; SYZYGIUM CUMINI EXTRACT; TINOSPORA CORDIFOLIA EXTRACT; TOCOPHEROL; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; AYURVEDA; CATARACT; CATARACT EXTRACTION; CATARACTOGENESIS; CONFORMATIONAL TRANSITION; DIET SUPPLEMENTATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; EYE INFECTION; EYE INFLAMMATION; HUMAN; NANOBIOTECHNOLOGY; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; OSMOSIS; OXIDATION; PATHOPHYSIOLOGY; PHASE SEPARATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SUSTAINED RELEASE PREPARATION;

AYURVEDIC TREATMENT; CAROTENOIDS; FLAVONOIDS; NANOENCAPSULATION.; OXIDATIVE MODIFICATION; PHASE SEPARATION;

ANTIOXIDANTS; CATARACT; CRYSTALLINS; FLAVONOIDS; HUMANS; HYDROXYBENZOATES; LACTOFERRIN; MEDICINE, AYURVEDIC; NANOMEDICINE; NANOTECHNOLOGY; OSMOTIC PRESSURE; OXIDATION-REDUCTION; PHASE TRANSITION; PROTEIN CONFORMATION; VITAMINS;

EID: 84887021321     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.07.068     Document Type: Review

References (117)

1. Rafferty N.S. The Ocular Lens; Structure Function and Pathology 1985, Marcel Dekker Inc, New York.
2. David A., Quillen M.D. Common causes of vision loss in elderly patients. Am. Fam. Physician 1999, 60:99-108.
3. Pascoliniand D., Mariotti S.P.M. Global estimates of visual impairment: 2010. Br. J. Ophthalmol. 2012, 96:614-618.
4. Chan E., Mahrooand O.A., Spalton D.J. Complications of cataract surgery. Clin. Exp. Optom. 2010, 93:379-389.
5. Reddy G.B., Reddy P.Y., Vijayalakshmi A., Kumar M.S., Suryanarayana P., Sesikeran B. Effect of long-term dietary manipulation on the aggregation of rat lens crystallins: role of alpha-crystallin chaperone function. Mol. Vis. 2002, 8:298-305.
6. Toh T., Morton J., Coxonand J., Elder M.J. Medical treatment of cataract. Clin. Exp. Ophthalmol. 2007, 35:664-671.
7. Agteand V., Tarwadi K. The importance of nutrition in the prevention of ocular disease with special reference to cataract. Ophthalmic Res. 2010, 44:166-172.
8. Moreau K.L., King J.A. Protein misfolding and aggregation in cataract disease and prospects for prevention. Trends Mol. Med. 2012, 18:273-282.
9. Shambhu D.C., Varma D., Sharma Y.R., Kuck J.F., Richards R.D. Oxidative stress on lens and cataract formation: role of light and oxygen. Curr. Eye Res. 1984, 3:35-57.
10. Garner M.H., Spector A. Selective oxidation of cysteine and methionine in normal and senile cataractous lenses. PNAS 1980, 77:1274-1277.
11. Linetsky M., James H.L., Ortwerth B.J. Spontaneous generation of superoxide anion by human lens proteins and by calf lens proteins ascorbylated in vitro. Exp. Eye Res. 1999, 69:239-248.
12. Altomare E., Grattagliano I., Vendemaile G., Micelli-Ferrari T., Signorile A., Cardia L. Oxidative protein damage in human diabetic eye: evidence of a retinal participation. Eur. J. Clin. Invest. 1997, 27:141-147.
13. Kyselova Z., Garcia S.J., Gajdosikova A., Gajdosik A., Stefek M. Temporal relationship between lens protein oxidation and cataract development in streptozotocin-induced diabetic rats. Physiol. Res. 2005, 54:49-56.
14. Williams D.L. Oxidation, antioxidants and cataract formation: a literature review. Vet. Ophthalmol. 2006, 9:292-298.
15. Takemotoand L., Sorensen C.M. Protein-protein interactions and lens transparency. Exp. Eye Res. 2008, 87:496-501.
16. Takemoto L.J. Beta A3/A1 crystallin from human cataractous lens contains an intramolecular disulfide bond. Curr. Eye Res. 1997, 16:719-724.
17. Takemoto L.J. Oxidation of cysteine residues from alpha-A crystallin during cataractogenesis of the human lens. Biochem. Biophys. Res. Commun. 1996, 223:216-220.
18. Takemotoand L., Boyle D. Increased deamidation of asparagine during human senile cataractogenesis. Mol. Vis. 2000, 6:164-168.
19. Hains P.G., Truscott R.J. Post-translational modifications in the nuclear region of young, aged, and cataract human lenses. J. Proteome Res. 2007, 6:3935-3953.
20. Kinoshita J.H. Mechanisms initiating cataract formation. Proctor lecture. Invest. Ophthalmol. 1974, 13:713-724.
21. van Heyningen R. Sugar alcohols in the pathogenesis of galactose and diabetic cataracts. Birth Defects Orig. Artic. Ser. 1976, 12:295-303.
22. Clark J.I., Steele J.E. Phase-separation inhibitors and prevention of selenite cataract. PNAS 1992, 89:1720-1724.
23. Delaye M., Clark J.I., Benedek G.B. Coexistence curves for the phase separation in the calf lens cytoplasm. Biochem. Biophys. Res. Commun. 1981, 100:908-914.
24. Clark J.I., Carper D. Phase separation in lens cytoplasm is genetically linked to cataract formation in the Philly mouse. PNAS 1987, 84:122-125.
25. Siezen R.J., Fisch M.R., Slingsby C., Benedek G.B. Opacification of gamma-crystallin solutions from calf lens in relation to cold cataract formation. PNAS 1985, 82:1701-1705.
26. Benedek G.B. The molecular basis of cataract formation. Ciba Found. Symp. 1984, 106:237-247.
27. Tardieu A., Veretout F., Kropand B., Slingsby C. Protein interactions in the calf eye lens: interactions between beta-crystallins are repulsive whereas in gamma-crystallins they are attractive. Eur. Biophys. J. 1992, 21:1-12.
28. Tanaka T., Ishimoto C., Chylack L.T. Phase separation of a protein-water mixture in cold cataract in the young rat lens. Science 1977, 197:1010-1012.
29. Ishimoto C., Goalwin P.W., Sun S.T., Nishio I., Tanaka T. Cytoplasmic phase separation in formation of galactosemic cataract in lenses of young rats. PNAS 1979, 76:4414-4416.
30. Babizhayev M.A., Deyev A.I., Yermakova V.N., Semiletov Y.A., Davydova N.G., Doroshenko V.S., Zhukotskii A.V., Goldman I.M. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D 2002, 3:87-103.
31. Gupta P.P., Pandey D.N., Pandey D.J., Sharma A.L., Srivastava R.K., Mishra S.S. Aspirin in experimental cataractogenesis. Indian J. Med. Res. 1984, 80:703-707.
32. Blakytnyand R., Harding J.J. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp. Eye Res. 1992, 54:509-518.
33. Guglielmotti A., Capezzone De Joannon A., Cazzolla N., Marchetti M., Soldo L., Cavallo G., Pinza M. Radical scavenger activity of bendazac, an anticataract non-steroidal anti-inflammatory agent. Pharmacol. Res. 1995, 32:369-373.
34. Balfour J.A., Clissold S.P. Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs 1990, 39:575-596.
35. Datiles M., Fukui H., Kuwabaraand T., Kinoshita J.H. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study. Invest. Ophthalmol. Vis. Sci. 1982, 22:174-179.
36. Biswas S., Harris F., Singh J., Phoenix D.A. The in vitro retardation of porcine cataractogenesis by the calpain inhibitor, SJA6017. Mol. Cell. Biochem. 2004, 261:169-173.
37. Grover J.K., Yadavand S., Vats V. Medicinal plants of India with anti-diabetic potential. J. Ethnopharmacol. 2002, 81:81-100.
38. Gacche R.N., Dhole N.A. Aldose reductase inhibitory, anti-cataract and antioxidant potential of selected medicinal plants from the Marathwada region, India. Nat. Prod. Res. 2011, 25:760-763.
39. Hassan Argani S.B., Ghorbanihaghjo A., Javadzadeh A., Mesgari M., Rashidi M. Preventive effect of onion juice on selenite-induced experimental cataract. Indian J. Ophthalmol. 2009, 57:p185.
40. + ATPase activity in sciatic nerves of streptozotocin-induced diabetic rats. Phytomedicine 1998, 5:121-127.
41. Muthuswamy U., Kuppusamy A., Vivekanandhan L., Thirumalaisamy S.A., Varadharajan S. Anticataract and antioxidant activities of Citrus aurantium L. peel extract against naphthalene induced cataractogenesis in rats. J. Pharm. Res. 2011, 4:680-682.
42. Devi V.G., Rooban B.N., Sasikala V., Sahasranamam V., Abraham A. Isorhamnetin-3-glucoside alleviates oxidative stress and opacification in selenite cataract in vitro. Toxicol. In Vitro 2010, 24:1662-1669.
43. Halder N., Joshi S., Gupta S.K. Lens aldose reductase inhibiting potential of some indigenous plants. J. Ethnopharmacol. 2003, 86:113-116.
44. Nair N.K., Patel K., Gandhi T. Effect of aqueous extract of Embelica officinalis on selenite induced cataract in rats. Iran. J. Pharm. Res. 2010, 9:147-152.
45. Lija Y., Biju P.G., Reeni A., Cibin T.R., Sahasranamam V., Abraham A. Modulation of selenite cataract by the flavonoid fraction of Emilia sonchifolia in experimental animal models. Phytother. Res. 2006, 20:1091-1095.
46. Jang D.S., Yoo N.H., Kim N.H., Lee Y.M., Kim C.S., Kim J., Kim J.H., Kim J.S. 3,5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein glycation, aldose reductase, and cataractogenesis. Biol. Pharm. Bull. 2010, 33:329-333.
47. Ertekin M.V., Kocer I., Karslioglu I., Taysi S., Gepdiremen A., Sezen O., Balci E., Bakan N. Effects of oral Ginkgo biloba supplementation on cataract formation and oxidative stress occurring in lenses of rats exposed to total cranium radiotherapy. Jpn. J. Ophthalmol. 2004, 48:499-502.
48. Rathi SS, Grover JK, Vikrant V., Biswas N.R. Prevention of experimental diabetic cataract by Indian ayurvedic plant extracts. Phytother. Res. 2002, 16:774-777.
49. Sasikala V., Rooban B.N., Priya S.G., Sahasranamam V., Abraham A. Moringa oleifera prevents selenite-induced cataractogenesis in rat pups. J. Ocul. Pharmacol. Ther. 2010, 26:441-447.
50. Dailami K.N., Azadbakht M., Pharm Z.R., Lashgari M. Prevention of selenite-induced cataractogenesis by Origanum vulgare extract. Pak. J. Biol. Sci. 2010, 13:743-747.
51. Vats V., Yadav S.P., Biswas N.R., Grover J.K. Anti-cataract activity of Pterocarpus marsupium bark and Trigonella foenum-graecum seeds extract in alloxan diabetic rats. J. Ethnopharmacol. 2004, 93:289-294.
52. Rooban B.N., Sasikala V., Sahasranamam V., Abraham A. Amelioration of selenite toxicity and cataractogenesis in cultured rat lenses by Vitex negundo. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:685-692.
53. Moure A., Cruz J.M., Franco D., Domínguez J.M., Sineiro J., Domínguez H., Núñez M.J., Parajó J.C. Natural antioxidants from residual sources. Food Chem. 2001, 72:145-171.
54. Sakihama Y., Cohen M.F., Grace S.C., Yamasaki H. Plant phenolic antioxidant and prooxidant activities: phenolics-induced oxidative damage mediated by metals in plants. Toxicology 2002, 177:67-80.
55. Brewer M.S. Natural antioxidants: sources, compounds, mechanisms of action, and potential applications. Compr. Rev. Food Sci. Food Saf. 2011, 10:221-247.
56. Rice-Evans C. Flavonoid antioxidants. Curr. Med. Chem. 2001, 8:797-807.
57. Saraswat M., Suryanarayana P., Reddy P.Y., Patil M.A., Balakrishna N., Reddy G.B. Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats. Mol. Vis. 2010, 16:1525-1537.
58. Ongand K.C., Khoo H.E. Biological effects of myricetin. Gen. Pharmacol. 1997, 29:121-126.
59. Akileshwari C., Muthenna P., Saraswat M., Reddy B.G. Inhibition of advanced glycation end-product formation on eye lens protein by rutin. Br. J. Nutr. 2011, 1-9.
60. Zhang J., Mao X., Zhou Y. Silybin decreases erythrocytic sorbitol level and improves peripheral nerve conduction velocity in patients with non-insulin dependent diabetes mellitus. CJIM 1995, 1:84-86.
61. Morimitsu Y., Yoshida K., Esaki S., Hirota A. Protein glycation inhibitors from thyme (Thymus vulgaris). Biosci. Biotechnol. Biochem. 1995, 59:2018-2021.
62. Varmaand S.D., Kinoshita J.H. Inhibition of lens aldose reductase by flavonoids-their possible role in the prevention of diabetic cataracts. Biochem. Pharmacol. 1976, 25:2505-2513.
63. Ghoshand D., Konishi T. Anthocyanins and anthocyanin-rich extracts: role in diabetes and eye function. Asia-Pac. J. Clin. Nutr. 2007, 16:200-208.
64. Morimitsu Y., Kubota K., Tashirob T., Hashizumec E., Kamiyac T., Osawa T. Inhibitory effect of anthocyanins and colored rice on diabetic cataract formation in the rat lenses. Int. Congr. Ser. 2002, 1245:503-508.
65. Osakabe N., Yamagishi M., Natsume M., Yasuda A., Osawa T. Ingestion of proanthocyanidins derived from cacao inhibits diabetes-induced cataract formation in rats. Exp. Biol. Med. (Maywood) 2004, 229:33-39.
66. Huang R., Shi F., Lei T., Song Y., Hughes C.L., Liu G. Effect of the isoflavonegenistein against galactose-induced cataracts in rats. Exp. Biol. Med. (Maywood) 2007, 232:118-125.
67. Cornish K.M., Williamson G., Sanderson J. Quercetin metabolism in the lens: role in inhibition of hydrogen peroxide induced cataract. Free Radic. Biol. Med. 2002, 33:63-70.
68. Lee S.M., Ko I.G., Kim S.E., Kim D.H., Kang B.N. Protective effect of catechin on apoptosis of the lens epithelium in rats with N-methyl-N-nitrosourea-induced cataracts. Korean J. Ophthalmol. 2010, 24:101-107.
69. Morton L.W., Abu-Amsha Caccetta R., Puddey I.B., Croft K.D. Chemistry and biological effects of dietary phenolic compounds: relevance to cardiovascular disease. Clin. Exp. Pharmacol. Physiol. 2000, 27:152-159.
70. Gale C.R., Hall N.F., Phillips D.I., Martyn C.N. Plasma antioxidant vitamins and carotenoids and age-related cataract. Ophthalmology 2001, 108:1992-1998.
71. Sakthivel M., Elanchezhian R., Ramesh E., Isai M., Jesudasan C.N., Thomas P.A., Geraldine P. Prevention of selenite-induced cataractogenesis in Wistar rats by the polyphenol, ellagic acid. Exp. Eye Res. 2008, 86:251-259.
72. Manikandan R., Thiagarajan R., Beulaja S., Chindhu S., Mariammal K., Sudhandiran G., Arumugam M. Anti-cataractogenic effect of curcumin and aminoguanidine against selenium-induced oxidative stress in the eye lens of Wistar rat pups: an in vitro study using isolated lens. Chem. Biol. Interact. 2009, 181:202-209.
73. Doganay S., Turkoz Y., Evereklioglu C., Er H., Bozaran M., Ozerol E. Use of caffeic acid phenethyl ester to prevent sodium-selenite-induced cataract in rat eyes. J. Cataract Refract. Surg. 2002, 28:1457-1462.
74. Kim C.S., Kim J., Lee Y.M., Sohn E., Jo K., Kim J.S. Inhibitory effects of chlorogenic acid on aldose reductase activity in vitro and cataractogenesis in galactose-fed rats. Arch. Pharm. Res. 2011, 34:847-852.
75. Chethan S., Dharmesh S.M., Malleshi N.G. Inhibition of aldose reductase from cataracted eye lenses by finger millet (Eleusine coracana) polyphenols. Bioorg. Med. Chem. 2008, 16:10085-10090.
76. Lodovici M., Caldini S., Morbidelli L., Akpan V., Ziche M., Dolara P. Protective effect of 4-coumaric acid from UVB ray damage in the rabbit eye. Toxicology 2009, 255:1-5.
77. Hegdeand K.R., Varma S.D. Protective effect of ascorbate against oxidative stress in the mouse lens. Biochim. Biophys. Acta. 2004, 1670:12-18.
78. Mody V.C., Kakar M., Elfving A., Soderbergand P.G., Lofgren S. Ascorbate in the rat lens: dependence on dietary intake. Ophthalmic Res. 2005, 37:142-149.
79. Yokoyama T., Sasaki H., Giblin F.J., Reddy V.N. A physiological level of ascorbate inhibits galactose cataract in guinea pigs by decreasing polyol accumulation in the lens epithelium: a dehydroascorbate-linked mechanism. Exp. Eye Res. 1994, 58:207-218.
80. Booth V.H., Bradford M.P. Tocopherol contents of vegetables and fruits. Br. J. Nutr. 1963, 17:575-581.
81. Creighton M.O., Ross W.M., Stewart-DeHaan P.J., Sanwaland M., Trevithick J.R. Modelling cortical cataractogenesis VII: Effects of vitamin E treatment on galactose-induced cataracts. Exp. Eye Res. 1985, 40:213-222.
82. Wang J., Lofgren S., Dong X., Galichanin K., Soderberg P.G. Dose-response relationship for alpha-tocopherol prevention of ultraviolet radiation induced cataract in rat. Exp. Eye Res. 2011, 93:91-97.
83. Kojima S.Y.M., Murano H. Low vitamin E level as a subliminal risk factor in a rat model of prednisolone-induced cataract. Invest. Ophthalmol. Vis. Sci. 2002, 43:1116-1120.
84. Burrow H., Kanwar R.K., Kanwar J.R. Antioxidant enzyme activities of iron-saturated bovine lactoferrin (Fe-bLf) in human gut epithelial cells under oxidative stress. Med. Chem. 2011, 7:224-230.
85. Moore S.A., Anderson B.F., Groom C.R., Haridas M., Baker E.N. Three-dimensional structure of diferric bovine lactoferrin at 2.8 A resolution. J. Mol. Biol. 1997, 274:222-236.
86. Gibbons J.A., Kanwar R.K., Kanwar J.R. Lactoferrin and cancer in different cancer models. Front Biosci. (Schol Ed) 2011, 3:1080-1088.
87. Kumar R., Parmar I.P., Chhillar N., Lal H. Tear lactoferrin concentration during postoperative ocular inflammation in cataract surgery. Acta. Ophthalmol. Scand. 1997, 75:142-144.
88. Kanwar J.R., Mahidharaand G., Kanwar R.K. Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. Nanomedicine (Lond) 2012, 7:1521-1550.
89. Lee V.H., Robinson J.R. Topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol. Ther. 1986, 2:67-108.
90. Idrees F., Vaideanu D., Fraser S.G., Sowden J.C., Khaw P.T. A review of anterior segment dysgeneses. Surv. Ophthalmol. 2006, 51:213-231.
91. Ahmed I., Patton T.F. Importance of the noncorenal absorption route in tropical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 1985, 26:584-587.
92. Ratnam D.V., Ankola D.D., Bhardwaj V., Sahana D.K., Kumar M.N. Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J. Control Release 2006, 113:189-207.
93. Wadhwa S., Paliwal R., Paliwaland S.R., Vyas S.P. Nanocarriers in ocular drug delivery: an update review. Curr. Pharm. Des. 2009, 15:2724-2750.
94. Badawi A.A., El-Laithy H.M., El-Qidraand R., El-dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch. Pharm. Res. 2008, 8:1040-1049.
95. Liu Z., Li J., Nie S., Liu H., Ding P., Pan W. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int. J. Pharm. 2006, 315:12-17.
96. Gavini C.P., Cossu E., Alvarez M., Saettone M.G., Giunchedi M.F.P. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. Eur. J. Pharm. Biopharm. 2003, 57:207-212.
97. Herrero-Vanrell R., Fernandez-Carballido A., Frutos G., Cadorniga R. Enhancement of the mydriatic response to tropicamide by bioadhesive polymers. J. Ocul. Pharmacol. Ther. 2000, 16:419-428.
98. Fresta M., Fontana G., Bucolo C., Cavallaro G., Giammona G., Puglisi G. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. J. Pharm. Sci. 2001, 90:288-297.
99. Pignatello R., Bucolo C., Spedalieri G., Maltese A., Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002, 23:3247-3255.
100. Kompella U.B., Sundaram S., Raghava S., Escobar E.R. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol. Vis. 2006, 12:1185-1198.
101. El-Kamel A.H. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int. J. Pharm. 2002, 241:47-55.
102. Budai L., Hajdu M., Budai M., Grof P., Beni S., Noszal B., Klebovich I., Antal I. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int. J. Pharm. 2007, 343:34-40.
103. Yenice I., Mocan M.C., Palaska E., Bochot A., Bilensoy E., Vural I., Irkec M., Hincal A.A. Hyaluronic acid coated poly-epsilon-caprolactonenanospheres deliver high concentrations of cyclosporine A into the cornea. Exp. Eye Res. 2008, 87:162-167.
104. Aggarwal D., Pal D., Mitra A.K., Kaur I.P. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int. J. Pharm. 2007, 338:21-26.
105. Eljarrat-Binstock E., Raiskup F., Stepensky D., Domb A.J., Frucht-Pery J. Delivery of gentamicin to the rabbit eye by drug-loaded hydrogel iontophoresis. Invest. Ophthalmol. Vis. Sci. 2004, 45:2543-2548.
106. Parveen S., Misraand R., Sahoo S.K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012, 8:147-166.
107. Schachar R.A., Wei C., Boon K.W., Barbara K.P., Xing Z., Lun M. Diffusion of nanoparticles into the capsule and cortex of a crystalline lens. Nanotechnology 2008, 19:025102.
108. Barbara K.P., Yuebin L., Akeel A.Y., Liza M.C., Ronald A.S., Wei C. Nanoceria have no genotoxic effect on human lens epithelial cells. Nanotechnology 2010, 21:35102-35108.
109. Kumari A., Yadav S.K., Pakade Y.B., Kumar V., Singh B., Chaudhary A., Yadav S.C. Nanoencapsulation and characterization of Albizia chinensis isolated antioxidant quercitrin on PLA nanoparticles. Colloids Surf., B: Biointerfaces 2011, 82:224-232.
110. Haaseand S.C., Chung K.C. An evidence-based approach to treating thumb carpometacarpal joint arthritis. Plast. Reconstr. Surg. 2011, 127:918-925.
111. Matsuda H., Cai H., Kubo M., Tosaand H., Iinuma M. Study on anti-cataract drugs from natural sources. II. Effects of buddlejaeflos on in vitro aldose reductase activity. Biol. Pharm. Bull. 1995, 18:463-466.
112. Rooban B.N., Sasikala V., Gayathri Devi V., Sahasranamam V., Abraham A. Prevention of selenite induced oxidative stress and cataractogenesis by luteolin isolated from Vitex negundo. Chem. Biol. Interact. 2012, 196:30-38.
113. Mahajan K.N., Singhai A.K., Vadnere G.P. Investigation on anticataract activity of Triphala Ghrita. Eur. J. Chem. 2011, 8:1438-1443.
114. Brown L., Rimm E.B., Seddon J.M., Giovannucci E.L., Chasan-Taber L., Spiegelman D., Willett W.C., Hankinson S.E. A prospective study of carotenoid intake and risk of cataract extraction in US men. Am. J. Clin. Nutr. 1999, 70:517-524.
115. Gupta S.K., Kalaiselvan V., Srivastava S., Agrawal S.S., Saxena R. Evaluation of anticataract potential of Triphala in selenite-induced cataract: In vitro and in vivo studies. J. Ayurveda Integr. Med. 2010, 1:280-286.
116. Moeller S.M., Jacques P.F., Blumberg J.B. The potential role of dietary xanthophylls in cataract and age-related macular degeneration. J. Am. Coll. Nutr. 2000, 19:522S-527S.
117. Wu T.H., Liao J.H., Hou W.C., Huang F.Y., Maher T.J., Hu C.C. Astaxanthin protects against oxidative stress and calcium-induced porcine lens protein degradation. J. Agric. Food Chem. 2006, 54:2418-2423.